Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study

被引:57
作者
Cook, IA [1 ]
Leuchter, AF [1 ]
Morgan, ML [1 ]
Stubbeman, W [1 ]
Siegman, B [1 ]
Abrams, M [1 ]
机构
[1] Univ Calif Los Angeles, Inst Neuropsychiat, Lab Behav Pharmacol, Los Angeles, CA 90024 USA
关键词
treatment resistant depression; cordance; EEG; treatment response; antidepressant medications; biomarker;
D O I
10.1016/j.jpsychires.2004.12.002
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Previous studies in unipolar depression have shown that early decreases in prefrontal values of the QEEG cordance measure identified responders to pharmacotherapy. These studies have all examined individuals who were drug-free prior to the first physiologic assessment, yet in the clinical management of treatment resistant depression (TRD), many patients undergo changes in treatment without a drug-free interval between treatments. Here, we investigated whether cordance decreases were associated with response in Stage I TRD subjects without wash-out between treatment trials. Awake EEGs were recorded from 12 adults with unipolar depression. Subjects were receiving naturalistic treatment, had failed SSRI monotherapy, and were starting a new treatment prescribed by their treating psychiatrists. EEG data were recorded before starting the new treatment and after approximately 1 week. Six of the 12 subjects responded to treatment after 8-10 weeks. Five of the six responders showed an early cordance decreases, compared with two of the six nonresponders (accurate characterization in 75% of the cases). Consistent with previous treatment trials, decreases in prefrontal cordance differentiated responders from nonresponders in this setting as well. These findings suggest that cordance biomarkers may be a useful tool in effectiveness trials that parallel clinical practices in SSRI nonresponders, and may not require a wash-out period between treatments. (c) 2005 Published by Elsevier Ltd.
引用
收藏
页码:461 / 466
页数:6
相关论文
共 43 条
[1]   Effect of the 5-HT1A partial agonist buspirone on regional brain electrical activity in man:: a functional neuroimaging study using low-resolution electromagnetic tomography (LORETA) [J].
Anderer, P ;
Saletu, B ;
Pascual-Marqui, RD .
PSYCHIATRY RESEARCH-NEUROIMAGING, 2000, 100 (02) :81-96
[2]  
[Anonymous], 2000, Am J Psychiatry, V157, P1
[3]   Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy -: Preliminary findings [J].
Brody, AL ;
Saxena, S ;
Stoessel, P ;
Gillies, LA ;
Fairbanks, LA ;
Alborzian, S ;
Phelps, ME ;
Huang, SC ;
Wu, HM ;
Ho, ML ;
Ho, MK ;
Au, SC ;
Maidment, K ;
Baxter, LR .
ARCHIVES OF GENERAL PSYCHIATRY, 2001, 58 (07) :631-640
[4]   Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine [J].
Brody, AL ;
Saxena, S ;
Silverman, DHS ;
Alborzian, S ;
Fairbanks, LA ;
Phelps, ME ;
Huang, SC ;
Wu, HM ;
Maidment, K ;
Baxter, LR .
PSYCHIATRY RESEARCH-NEUROIMAGING, 1999, 91 (03) :127-139
[5]  
BUCHNER A, 1997, GPOWER PRIORI POST H
[6]  
Cohen J., 1988, STAT POWER ANAL BEHA
[7]  
Cook I A, 2001, Semin Clin Neuropsychiatry, V6, P113, DOI 10.1053/scnp.2001.21844
[8]   Assessing the accuracy of topographic EEG mapping for determining local brain function [J].
Cook, IA ;
O'Hara, R ;
Uijtdehaage, SHJ ;
Mandelkern, M ;
Leuchter, AF .
ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1998, 107 (06) :408-414
[9]   Early changes in prefrontal activity characterize clinical responders to antidepressants [J].
Cook, IA ;
Leuchter, AF ;
Morgan, M ;
Witte, E ;
Stubbeman, WF ;
Abrams, M ;
Rosenberg, S ;
Uijtdehaage, SHJ .
NEUROPSYCHOPHARMACOLOGY, 2002, 27 (01) :120-131
[10]   The Texas Medication Algorithm Project: Report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder [J].
Crismon, ML ;
Trivedi, M ;
Pigott, TA ;
Rush, AJ ;
Hirschfeld, RMA ;
Kahn, DA ;
DeBattista, C ;
Nelson, JC ;
Nierenberg, AA ;
Sackeim, HA ;
Thase, ME .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (03) :142-156